Drugs · acquisition-cost intelligence
Valproic Acid
· ingredient valproate· VALPROIC ACID 250 mg/5mL; VALPROIC ACID 500 mg/10mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.03316
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other valproate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| Depakote | $0.08917 | +$0.05600 |
| divalproex sodium | $0.16834 | +$0.13520 |
| Depakote ER | $0.18706 | +$0.15390 |
| divalproex sodium | $0.18706 | +$0.15390 |
| Depakote Sprinkles | $0.19861 | +$0.16550 |
| Valproic | $0.23989 | +$0.20670 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.